vs
Side-by-side financial comparison of PTC THERAPEUTICS, INC. (PTCT) and VICOR CORP (VICR). Click either name above to swap in a different company.
PTC THERAPEUTICS, INC. is the larger business by last-quarter revenue ($164.7M vs $113.0M, roughly 1.5× VICOR CORP). VICOR CORP runs the higher net margin — 18.3% vs -82.0%, a 100.2% gap on every dollar of revenue. On growth, VICOR CORP posted the faster year-over-year revenue change (20.2% vs -22.7%). Over the past eight quarters, VICOR CORP's revenue compounded faster (14.7% CAGR vs -11.5%).
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
Vicor Corporation is a manufacturer of power modules headquartered in Andover, Massachusetts.
PTCT vs VICR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $164.7M | $113.0M |
| Net Profit | $-135.0M | $20.7M |
| Gross Margin | — | — |
| Operating Margin | -43.3% | 59.7% |
| Net Margin | -82.0% | 18.3% |
| Revenue YoY | -22.7% | 20.2% |
| Net Profit YoY | -104.8% | 713.9% |
| EPS (diluted) | $-1.63 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $113.0M | ||
| Q4 25 | $164.7M | $107.3M | ||
| Q3 25 | $211.0M | $110.4M | ||
| Q2 25 | $178.9M | $96.0M | ||
| Q1 25 | $1.2B | $94.0M | ||
| Q4 24 | $213.2M | $96.2M | ||
| Q3 24 | $196.8M | $93.2M | ||
| Q2 24 | $186.7M | $85.9M |
| Q1 26 | — | $20.7M | ||
| Q4 25 | $-135.0M | $46.5M | ||
| Q3 25 | $15.9M | $28.3M | ||
| Q2 25 | $-64.8M | $41.2M | ||
| Q1 25 | $866.6M | $2.5M | ||
| Q4 24 | $-65.9M | $10.2M | ||
| Q3 24 | $-106.7M | $11.6M | ||
| Q2 24 | $-99.2M | $-1.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | 55.4% | ||
| Q3 25 | — | 57.5% | ||
| Q2 25 | — | 95.9% | ||
| Q1 25 | — | 47.2% | ||
| Q4 24 | — | 52.4% | ||
| Q3 24 | — | 49.1% | ||
| Q2 24 | — | 49.8% |
| Q1 26 | — | 59.7% | ||
| Q4 25 | -43.3% | 14.6% | ||
| Q3 25 | 1.4% | 18.9% | ||
| Q2 25 | -19.5% | 47.3% | ||
| Q1 25 | 82.5% | -0.2% | ||
| Q4 24 | -76.2% | 9.6% | ||
| Q3 24 | -27.7% | 5.8% | ||
| Q2 24 | -21.5% | 0.2% |
| Q1 26 | — | 18.3% | ||
| Q4 25 | -82.0% | 43.4% | ||
| Q3 25 | 7.5% | 25.6% | ||
| Q2 25 | -36.3% | 42.9% | ||
| Q1 25 | 73.7% | 2.7% | ||
| Q4 24 | -30.9% | 10.7% | ||
| Q3 24 | -54.2% | 12.4% | ||
| Q2 24 | -53.1% | -1.4% |
| Q1 26 | — | $0.44 | ||
| Q4 25 | $-1.63 | $1.01 | ||
| Q3 25 | $0.20 | $0.63 | ||
| Q2 25 | $-0.83 | $0.91 | ||
| Q1 25 | $10.04 | $0.06 | ||
| Q4 24 | $-0.85 | $0.24 | ||
| Q3 24 | $-1.39 | $0.26 | ||
| Q2 24 | $-1.29 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9B | $404.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-205.3M | $754.1M |
| Total Assets | $2.9B | $804.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $404.2M | ||
| Q4 25 | $1.9B | $402.8M | ||
| Q3 25 | $1.7B | $362.4M | ||
| Q2 25 | $2.0B | $338.5M | ||
| Q1 25 | $2.0B | $296.1M | ||
| Q4 24 | $1.1B | $277.3M | ||
| Q3 24 | $1.0B | $267.6M | ||
| Q2 24 | $1.1B | $251.9M |
| Q1 26 | — | $754.1M | ||
| Q4 25 | $-205.3M | $711.6M | ||
| Q3 25 | $-155.8M | $630.1M | ||
| Q2 25 | $-206.5M | $608.6M | ||
| Q1 25 | $-185.8M | $580.3M | ||
| Q4 24 | $-1.1B | $570.1M | ||
| Q3 24 | $-1.1B | $554.6M | ||
| Q2 24 | $-980.2M | $537.2M |
| Q1 26 | — | $804.9M | ||
| Q4 25 | $2.9B | $785.8M | ||
| Q3 25 | $2.6B | $710.2M | ||
| Q2 25 | $2.6B | $693.5M | ||
| Q1 25 | $2.7B | $665.0M | ||
| Q4 24 | $1.7B | $641.1M | ||
| Q3 24 | $1.8B | $632.8M | ||
| Q2 24 | $1.9B | $613.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.3M | — |
| Free Cash FlowOCF − Capex | $-36.6M | — |
| FCF MarginFCF / Revenue | -22.3% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $702.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-34.3M | $15.7M | ||
| Q3 25 | $-66.3M | $38.5M | ||
| Q2 25 | $-58.3M | $65.2M | ||
| Q1 25 | $870.1M | $20.1M | ||
| Q4 24 | $-30.0M | $10.1M | ||
| Q3 24 | $-77.0M | $22.6M | ||
| Q2 24 | $-71.5M | $15.6M |
| Q1 26 | — | — | ||
| Q4 25 | $-36.6M | $10.2M | ||
| Q3 25 | $-69.7M | $34.5M | ||
| Q2 25 | $-59.6M | $59.0M | ||
| Q1 25 | $868.4M | $15.6M | ||
| Q4 24 | $-33.8M | $8.4M | ||
| Q3 24 | $-77.5M | $14.1M | ||
| Q2 24 | $-78.8M | $9.4M |
| Q1 26 | — | — | ||
| Q4 25 | -22.3% | 9.5% | ||
| Q3 25 | -33.1% | 31.2% | ||
| Q2 25 | -33.3% | 61.5% | ||
| Q1 25 | 73.8% | 16.6% | ||
| Q4 24 | -15.8% | 8.7% | ||
| Q3 24 | -39.4% | 15.2% | ||
| Q2 24 | -42.2% | 11.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 5.2% | ||
| Q3 25 | 1.6% | 3.6% | ||
| Q2 25 | 0.7% | 6.5% | ||
| Q1 25 | 0.1% | 4.8% | ||
| Q4 24 | 1.8% | 1.8% | ||
| Q3 24 | 0.3% | 9.1% | ||
| Q2 24 | 4.0% | 7.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.34× | ||
| Q3 25 | -4.17× | 1.36× | ||
| Q2 25 | — | 1.58× | ||
| Q1 25 | 1.00× | 7.93× | ||
| Q4 24 | — | 0.99× | ||
| Q3 24 | — | 1.95× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PTCT
Segment breakdown not available.
VICR
| Product revenue | $98.0M | 87% |
| Royalty revenue | $15.0M | 13% |
